# APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

> **NCT04858334** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 152 (estimated)

## Conditions studied

- Pancreatic Acinar Cell Carcinoma
- Pancreatic Adenosquamous Carcinoma
- Pancreatic Squamous Cell Carcinoma
- Resectable Pancreatic Acinar Cell Carcinoma
- Resectable Pancreatic Adenocarcinoma
- Resectable Pancreatic Adenosquamous Carcinoma
- Resectable Pancreatic Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Olaparib
- **DRUG:** Placebo Administration

## Key facts

- **NCT ID:** NCT04858334
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-22
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04858334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04858334, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04858334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*